Showing results (191-200 of 259) with videos related to

Sort By:
Pageof 26
Gynecologic Oncology|June 1, 1993
High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensityA Bonetti, S B Howell, E McClay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1993
Dose intensification of cisplatin chemotherapy through biweekly administrationS Kim, S B Howell, E McClay, et al.
Biochemical Pharmacology|May 25, 1993
Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitroA P Jekunen, D R Shalinsky, D K Hom, et al.
The Journal of Clinical Investigation|July 1, 1993
In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubulesR D Christen, A P Jekunen, J A Jones, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 10, 1998
Prediction-based threading of the hMSH2 DNA mismatch repair proteinM M de las Alas, R A de Bruin, L Ten Eyck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cellsS Aebi, D Fink, R Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
In vitro antineoplastic activity of a novel lanthionine-containing peptideH Zheng, D Fink, H Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1992
Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignanciesS L Berg, F M Balis, S Zimm, et al.
British Journal of Cancer|March 26, 1998
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cellsD Fink, S Nebel, P S Norris, et al.
Pageof 26